Contact this trialFirst, we need to learn more about you.
SGLT2 Inhibitor
Dapagliflozin for Cardiovascular Risk
Recruiting2 awardsPhase 2
Toronto
This trial looks at how a diabetes medication affects various aspects of heart and kidney health in people with and without diabetes.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.